Biomarkers · Chemical
A plain-language description with its source has not been added for this biomarker yet. What the laboratories say about the tests that measure it is below.
What the laboratory says this test is for
Myasthenia gravis (MG) is an autoimmune disorder affecting the neuromuscular junction. 80% of patients with generalized MG have serum antibodies to AChR - Blocking, Binding, or Modulating. Antibodies to MuSK make up a variable proportion of the remaining 20%.
Quest Diagnostics test directory, test code 93859
What the laboratory says this test is for
Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. AChR binding autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR modulating antibodies cross-link AChR molecules on cell surface, promoting internalization, and decreasing AChR surface density. The AChR binding and modulating antibody assays have similar sensitivities, but performing them together increases sensitivity of antibody detection by approximately 5%.
Quest Diagnostics test directory, test code 26474
What the laboratory says this test is for
Lambert-Eaton myasthenic syndrome is a paraneoplastic phenomena associated with small cell lung cancer. There is a decrease of voltage-gated calcium channels on presynaptic nerve terminals due to an auto-antibody reactive with the channels. There is an associated proximal muscle weakness and often coexisting thyroid autoimmune disease and vitiligo.
Quest Diagnostics test directory, test code 11306
What the laboratory says this test is for
Myasthenia Gravis is a neurological disorder characterized by a decrease in acetylcholine receptors. Patients exhibit skeletal muscle weakness and fatigability. Approximately 80% of patients with Myasthenia Gravis, excluding ocular involvement only, have detectable acetylcholine receptor antibody. There is a strong correlation between the presence of striated muscle antibody and the presence of thymoma.
Quest Diagnostics test directory, test code 10211
What the laboratory says this test is for
Myasthenia Gravis is a neurological disorder characterized by a decrease in acetylcholine receptors. Patients exhibit skeletal muscle weakness and fatigability. Approximately 80% of patients with Myasthenia Gravis, excluding ocular involvement only, have detectable acetylcholine receptor antibody.
Quest Diagnostics test directory, test code 10104
Everything above is drawn from the named sources and shown as they published it. Reference ranges belong to the laboratory that issued them and the population it named; they are not a universal normal. This page describes the biomarker in general and does not interpret anyone's result. For your own numbers, talk to a clinician, or use Aumnivida, which reads the same graph next to your records.
Found an error? Write to hello@biomarkerlens.com with the page link and the source that contradicts it.